Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?

Diabetes/metabolism Research and Reviews
Raffaella GentilellaAgostino Consoli

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are an important class of drugs with a well-established efficacy and safety profile in patients with type 2 diabetes mellitus. Agents in this class are derived from either exendin-4 (a compound present in Gila monster venom) or modifications of human GLP-1 active fragment. Differences among these drugs in duration of action (ie, short-acting vs long-acting), effects on glycaemic control and weight loss, immunogenicity, tolerability profiles, and administration routes offer physicians several options when selecting the most appropriate agent for individual patients. Patient preference is also an important consideration. The aim of this review is to discuss the differences between and similarities of GLP-1 RAs currently approved for clinical use, focusing particularly on the properties characterising the single short-acting and long-acting GLP-1 RAs rather than on their individual efficacy and safety profiles. The primary pharmacodynamic difference between short-acting (ie, exenatide twice daily and lixisenatide) and long-acting (ie, albiglutide, dulaglutide, exenatide once weekly, liraglutide, and semaglutide) GLP-1 RAs is that short-acting agents primarily delay gastric em...Continue Reading

References

Jul 4, 2002·The American Journal of Gastroenterology·Dhiraj YadavC S Pitchumoni
Sep 17, 2003·The Journal of Pharmacology and Experimental Therapeutics·Christian ThorkildsenJørgen Søberg Petersen
Oct 27, 2004·Diabetes Care·John B BuseUNKNOWN Exenatide-113 Clinical Study Group
Oct 19, 2005·Annals of Internal Medicine·Robert J HeineUNKNOWN GWAA Study Group
Jan 19, 2008·Journal of Behavioral Medicine·Karen S Ingersoll, Jessye Cohen
Aug 19, 2009·Diabetologia·D Russell-JonesUNKNOWN Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group
Feb 19, 2010·The New England Journal of Medicine·Mary Parks, Curtis Rosebraugh
Mar 11, 2010·Diabetes Care·John B BuseUNKNOWN DURATION-1 Study Group
Apr 29, 2010·Current Diabetes Reports·Mikkel Christensen, Filip K Knop
May 27, 2010·Diabetes/metabolism Research and Reviews·Wolfgang GlaesnerTom Bumol
Jan 5, 2011·Toxicon : Official Journal of the International Society on Toxinology·Brian L Furman
Feb 22, 2011·Gastroenterology·Michael ElashoffPeter C Butler
Jun 10, 2011·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Steven P MarsoJohn B Buse
Jul 13, 2011·Experimental Diabetes Research·Anne M RowzeeGiovanni Di Pasquale
Jan 12, 2012·Diabetes, Obesity & Metabolism·M S FinemanM Diamant
May 1, 2012·Diabetic Medicine : a Journal of the British Diabetic Association·G DerosaP Maffioli

❮ Previous
Next ❯

Citations

Nov 24, 2018·Diabetes/metabolism Research and Reviews·Evangelia KalaitzoglouKathryn M Thrailkill
Apr 28, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Victoria DivinoKirsi Norrbacka
May 6, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Raffaella GentilellaGiorgio Sesti
Nov 24, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Hitoshi IshiiMasakazu Takeuchi
May 12, 2020·United European Gastroenterology Journal·Anne-Marie Langmach WegebergChristina Brock
Aug 21, 2020·Postgraduate Medicine·Stephen A Brunton, Carol Wysham
Feb 1, 2020·Drugs·Lesley J Scott
Jun 26, 2020·Metabolic Syndrome and Related Disorders·Rona ZhouArthur Swislocki
Aug 7, 2020·JAAPA : Official Journal of the American Academy of Physician Assistants·Scott Urquhart, Stephen Willis
Aug 3, 2020·JAAPA : Official Journal of the American Academy of Physician Assistants·Scott Urquhart, Stephen Willis
Jan 30, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Yukiko OnishiMasakazu Takeuchi
Jul 19, 2019·Clinical Drug Investigation·Katherine A Lyseng-Williamson
Apr 10, 2020·F1000Research·Josh ReedVenkateswarlu Kanamarlapudi
Aug 28, 2020·Frontiers in Bioengineering and Biotechnology·Ruichen ZhaoXin Zhang
Sep 26, 2020·International Journal of Clinical Practice·Akshay B JainTina Vilsbøll
Oct 25, 2020·Diabetes/metabolism Research and Reviews·Thomas ForstPaolo Pozzilli
Dec 3, 2020·Pharmaceuticals·Ehtasham AhmadMelanie J Davies
Jan 11, 2021·Clinical Obesity·Andrej BelančićMarija Troskot Dijan
Feb 5, 2021·International Journal of Pharmaceutics·Noura G EissaAyat Allam
Dec 11, 2020·Diabetic Medicine : a Journal of the British Diabetic Association·Wasim HanifKamlesh Khunti
Nov 27, 2020·European Heart Journal Supplements : Journal of the European Society of Cardiology·Claudio Borghi, Alessio Bragagni
Oct 15, 2020·Reviews in Endocrine & Metabolic Disorders·Rout George KerrySabuj Sahoo
Feb 18, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Ildiko LingvayJay H Shubrook
Feb 18, 2021·Endocrinology·Jeffrey Gagnon
Nov 14, 2020·Current Opinion in Endocrinology, Diabetes, and Obesity·Vibha SinghalSonali Malhotra
Apr 2, 2019·Physiology & Behavior·N S Hernandez, H D Schmidt
Mar 26, 2021·Molecular Biology Reports·Amit GuptaAbdul Hafeez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Related Papers

Therapeutic Advances in Endocrinology and Metabolism
Jennifer M TrujilloSamuel L Ellis
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
Annachiara UccellatoreAntonio Ceriello
© 2022 Meta ULC. All rights reserved